Rademaker AW - Search Results

1

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.

Costa R, Carneiro BA, Agulnik M, Rademaker AW, Pai SG, Villaflor VM, Cristofanilli M, Sosman JA, Giles FJ. Costa R, et al. Among authors: rademaker aw. Oncotarget. 2017 Jan 31;8(5):8910-8920. doi: 10.18632/oncotarget.13315. Oncotarget. 2017. PMID: 27852042 Free PMC article. Review.

2

Genomic characterization of high-risk non-muscle invasive bladder cancer.

Meeks JJ, Carneiro BA, Pai SG, Oberlin DT, Rademaker A, Fedorchak K, Balasubramanian S, Elvin J, Beaubier N, Giles FJ. Meeks JJ, et al. Oncotarget. 2016 Nov 15;7(46):75176-75184. doi: 10.18632/oncotarget.12661. Oncotarget. 2016. PMID: 27750214 Free PMC article.

3

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.

Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK. Costa RB, et al. Oncotarget. 2018 Apr 24;9(31):22137-22146. doi: 10.18632/oncotarget.25154. eCollection 2018 Apr 24. Oncotarget. 2018. PMID: 29774128 Free PMC article.

4

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.

Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ. Santa-Maria CA, et al. Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721177 Free PMC article.

5

Indoleamine 2,3-dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer.

Rosenberg AJ, Wainwright DA, Rademaker A, Galvez C, Genet M, Zhai L, Lauing KL, Mulcahy MF, Hayes JP, Odell DD, Horbinski C, Komanduri S, Tetreault MP, Kim KA, Villaflor VM. Rosenberg AJ, et al. Oncotarget. 2018 May 4;9(34):23482-23493. doi: 10.18632/oncotarget.25235. eCollection 2018 May 4. Oncotarget. 2018. PMID: 29805749 Free PMC article.

6

Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial.

Carneiro BA, Konda B, Costa RB, Costa RLB, Sagar V, Gursel DB, Kirschner LS, Chae YK, Abdulkadir SA, Rademaker A, Mahalingam D, Shah MH, Giles FJ. Carneiro BA, et al. J Clin Endocrinol Metab. 2019 Dec 1;104(12):6193-6200. doi: 10.1210/jc.2019-00600. J Clin Endocrinol Metab. 2019. PMID: 31276163 Clinical Trial.

7

Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer.

Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ. Pai SG, et al. Among authors: rademaker aw. J Gastrointest Oncol. 2017 Oct;8(5):858-866. doi: 10.21037/jgo.2017.06.20. J Gastrointest Oncol. 2017. PMID: 29184690 Free PMC article.

8

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ. Costa R, et al. Among authors: rademaker aw. Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Cancer Treat Rev. 2017. PMID: 28279895 Review.

9

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.

Shah AN, Flaum L, Helenowski I, Santa-Maria CA, Jain S, Rademaker A, Nelson V, Tsarwhas D, Cristofanilli M, Gradishar W. Shah AN, et al. J Immunother Cancer. 2020 Feb;8(1):e000173. doi: 10.1136/jitc-2019-000173. J Immunother Cancer. 2020. PMID: 32060053 Free PMC article. Clinical Trial.

10

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.

Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ. Jain S, et al. Breast Cancer Res Treat. 2018 Sep;171(2):371-381. doi: 10.1007/s10549-018-4792-0. Epub 2018 May 30. Breast Cancer Res Treat. 2018. PMID: 29850984 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

591 results

Search Page